Kuros Biosciences Forecast, price target & analysts
CHF19.44
3.79%
SIX Swiss Exchange, Oct 21, 05:31 pm CEST.
Closed.
Why the stock moved Beta
ISIN
CH0325814116
Symbol
KURN
Industry
Kuros Biosciences Target price 2026 - Analyst rating & recommendation
Powered by
Kuros Biosciences Classifications & Recommendation
Buy
90%
Hold
10%
Kuros Biosciences Price Target
| Target Price | CHF33.66 |
| Price | CHF19.44 |
| Potential | |
| Number of Estimates | 6 |
| 6 Analysts have issued a price target Kuros Biosciences 2027 . The average Kuros Biosciences target price is CHF33.66. This is higher than the current stock price. The highest price target is , the lowest is . | |
| A rating was issued by 10 analysts: 9 Analysts recommend Kuros Biosciences to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Kuros Biosciences stock has an average upside potential 2027 of . Most analysts recommend the Kuros Biosciences stock at Purchase. |
Sales and Margin forecast 2026, 2027 & 2028
Create a premium account to unlock analyst estimates.
Learn more
Powered by
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million CHF | ??? | ??? |
| ??? | ??? | |
| EBITDA Margin | ??? | ??? |
| ??? | ??? |
6 Analysts have issued a sales forecast Kuros Biosciences 2026 . The average Kuros Biosciences sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
6 Analysts have issued an Kuros Biosciences EBITDA forecast 2026. The average Kuros Biosciences EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
Create a premium account to unlock analyst estimates.
Learn more
Powered by
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | ??? | ??? |
| ??? | ??? | |
| P/E | ??? | |
| EV/Sales | ??? |
Kuros Biosciences...
Current Kuros Biosciences Upgrades & Downgrades
Create a Premium account to unlock Upgrades/Downgrades.
Learn more
| Analyst | Rating | Action | Date |
|---|---|---|---|
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| ??? |
Locked
➜
Locked
|
Locked | ??? |
| Analyst Rating | Date |
|---|---|
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
|
Locked
???:
Locked
➜
Locked
|
??? |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
